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Last year, a new act, the Act on the Safety of Regenerative Med-
icine has been issued [1]. This Act covers all kinds of medical tech-
nologies using processed cells whose safety and efﬁcacy have not
yet been established. At present, it is assumed that the Act will
apply to not only clinical trials performed by academia but also
cell therapies administered in daily practice using processed cells
in general, including cancer therapies with immune cells and so-
called stem cell therapies for cosmetic purposes. Medical proce-
dures of established safety and efﬁcacy, such as widely performed
organ transplantations, are excluded from the scope of this Act.
Next, based on the concept of a risk-based approach, these medical
technologies are categorized into 3 classes depending on their
anticipated potential risk to human health, and the safety of indi-
vidual technologies in each class is subject to review through the
deﬁned procedures. The Ministry of Health, Labour and Welfare
(MHLW) showed their opinion that platelet rich plasma (PRP) injec-
tion is within the scope of this act in a Q&A issued on December 21
(2014). Recently, some clinicians and researchers expressed their
objection against this decision. However, we support this decision
since the safety and efﬁcacy of PRP injection are not established
yet, to our best knowledge, according to the outcomes of human
clinical studies [2]. In addition, relevant non clinical studies have1 Masayuki Yamato is a shareholder of CellSeed Inc.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).not been performed.We believe that this treatment is still at a stage
of experimental research, and not well established. We would like
to hear candid opinions from the members of the society on this
issue.References
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